期刊文献+

胚胎多巴胺神经元移植治疗帕金森病的实验研究 被引量:4

Intracerebral transplantation of embryonic dopamine neurons for Parkinson disease:An experimental study
下载PDF
导出
摘要 目的探讨胚胎多巴胺神经元移植对帕金森病大鼠的治疗作用。方法立体定向注射6-羟多巴胺建立帕金森病大鼠模型,随机分为对照组(n=12)和细胞移植组(n=12)。细胞移植组将荧光染料CM-DiI标记的大鼠胚胎多巴胺神经元立体定向注入帕金森病大鼠纹状体区,对照组于相同部位注入生理盐水。用阿扑吗啡诱导帕金森病大鼠旋转行为评估细胞移植的治疗作用。细胞移植8周后取大脑标本行冷冻切片,荧光显微镜下观察移植细胞在脑内存活情况。结果与对照组比较,移植多巴胺神经元能显著改善阿扑吗啡诱导帕金森病大鼠的异常旋转行为(P<0.01)。移植8周后,仅少量多巴胺神经元存活。结论多巴胺神经元移植可短期内改善帕金森病大鼠的运动障碍,但长期疗效不佳,可能与移植多巴胺神经元长期存活率较低有关。 Objective To explore the therapeutic effect of transplanted dopamine(DA)neurons in Parkinson disease(PD)rat models.Methods The PD rat models were established by stereotactic injection of 6-hydroxydopamine and then were randomly divided into control group(n=12)and cell transplanted group(n=12).The rat DA neurons labeled by fluorescent dye CM-DiI were injected stereotactically into the corpus striatum of PD rats in cell-transplanted group and physiologic saline was injected into the same site of rats in control group.The therapeutic effect of cell transplantation was evaluated through rotations of PD rats induced by apomorphine(APO).Frozen sections of the brain samples were prepared 8 weeks after transplantation and the survival of transplanted cells was observed under fluorescence microscope.Results Compared with control group,the transplanted DA neurons more significantly improved the abnormal rotational behavior of PD rats induced by APO(P〈0.01).Eight weeks after transplantation,only a few transplanted cells survived.Conclusions Transplantation of DA neurons can significantly improve abnormal behavior of PD rats in short term.However,the long-term therapeutic effect is poor,which may be related to the low survival rate of transplanted DA neurons in long term.
出处 《中国微侵袭神经外科杂志》 CAS 北大核心 2010年第8期366-368,共3页 Chinese Journal of Minimally Invasive Neurosurgery
基金 云南省教育厅科学研究基金(编号:09Y0153) 昆明医学院第一附属医院博士启动基金
关键词 帕金森病 多巴胺 神经元 细胞移植 胚胎 Parkinson disease dopamine neurons cell transplantation embryo
  • 相关文献

参考文献11

  • 1Zhang ZX, Roman GC, Hong Z, e t al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai [J]. Lancet, 2005, 365(9459): 595-597.
  • 2Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease [J]. Arch Neurol, 2005, 62(3): 353-357.
  • 3Fahn S. Levodopa in the treatment of Parkinson's disease [J]. J Neural Transm Suppl, 2006, 71:1-15.
  • 4Paul G, Alan YH, Li JY, e t al. Transplantation in Parkinson's disease: The future looks bright [J]. Adv Exp Med Biol, 2006, 557: 221-248.
  • 5Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease [J]. Neurotox Res, 2007, 11 (3-4): 151-167.
  • 6邓兴力,刘如恩,雷德强,冯忠堂.帕金森病模型研究进展[J].中国比较医学杂志,2008,18(7):63-67. 被引量:4
  • 7Freed CR, Leehey MA, Zawada M, et al. Do patients with Parkinson's disease benefit fi'om embryonic dopamine cell transplantation [J]? J Neurol, 2003, 250(Supp! 3): 44-46.
  • 8Cesaro P. The design of clinical trials for cell transplantation into the central nervous system [J]. NeuroRx, 2004, 1(4): 492- 499.
  • 9Bjorklund A. Cell therapy for Parkinson's disease: problems and prospects [J]. Novartis Found Symp, 2005, 265: 174- 187, 204-211.
  • 10李东,崔磊,舒朝锋,柳向东,张英,柴岗,刘伟,曹谊林.荧光活性染料DiI标记观察人骨髓基质干细胞与部分脱钙骨粘附的实验研究[J].中华创伤骨科杂志,2004,6(3):311-314. 被引量:20

二级参考文献25

  • 1Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease[J]. Neuro Rx, 2004, 1(1):139- 154.
  • 2Fornai F, Lenzi P, Gesi M, et al. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson' s disease [ J]. Curr Drug Targets CNS Neurol Disord, 2003, 2(3) : 149 - 152.
  • 3Allam MF, Del Castillo AS, Navajas RF. Parkinson's disease risk factors: genetic, environmental, or both[J]? Neurol Res, 2005, 27 (2) :206 - 208.
  • 4Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence [J ]? Environ Health Perspect,2005, 113(9) : 1234 - 1238.
  • 5Lester J, Otero-Siliceo E. Parkinson's disease and genetics [ J ]. Neurologist, 2006, 12(5) :240 - 244.
  • 6Litvan I, Halliday G, Hallett M, et al. The etiopathogenesis of Parkinson disease and suggestions for future research [ J ]. J Neuropathol Exp Neurol, 2007, 66(4) :251 - 257.
  • 7Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis[J]. Science, 1983, 219(4587) :979 - 980.
  • 8Watanabe Y, Himeda T, Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease [ J ]. Med Sci Monit, 2005,11(1):RA17-23.
  • 9Kitamura Y, Kakimura J, Taniguchi T, et al. Protective effect of talipexole on MPTP treated planarian, a unique parkinsonian worm model[J]. Jpn J Pharmacol, 1998, 78(1) :23 - 29.
  • 10Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson' s disease[J]. Brain Res Mol Brain Res, 2005, 134(1) :57- 66.

共引文献22

同被引文献36

  • 1刘新权,景猛,栾彧,姜蓓,刘恩重,侯月玮.不同MR扫描序列对脑内移植SPIO标记神经干细胞大鼠的成像对比研究[J].中国微侵袭神经外科杂志,2004,9(12):560-562. 被引量:6
  • 2Schapira A H, Jenner P. Etiology and pathogenesis of Parkinson's disease [ J ]. Mov Disord, 2011, 26 ( 6 ) : 1049-1055.
  • 3George P, Charles W. The rat brain in stereotaxic coordi- nates[M]. 5th ed. San Diego: Elsevier, 2007: 456.
  • 4Choi D Y, Liu M, Hunter R L, et al. Striatal neuroin- flammation promotes Parkinsonism in rats [ J ]. Plos One, 2009, 4 ( 5 ) : e5482.
  • 5Zaheer F, Slevin J T. Trichloroethylene and Parkinson disease [ J ]. Neurol Clin, 2011, 29 (3) :657-665.
  • 6Meredith G E, Sonsalla P K, Chesselet M F. Animal models of Parkinson's disease progression[J]. Acta Neu- ropathol, 2008, 115(4) :385-398.
  • 7Philippens I H, Wubben J A, Finsen B, et al. Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinson- ism in the MPTP marmoset model [ J ]. J Neuroimmune Pharrnacol, 2013, 8(3) :715-726.
  • 8邓兴力,雷德强,刘如恩,等.帕金森病大鼠模型的建立[J].亡东医学,2012,33(3):313-315.
  • 9Berretta N, Freestone P S, Guatteo E, et al. Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro [ J ]. Neurotoxicology, 2005, 26(5) :869-881.
  • 10Olanow CW. The scientific basis for the current treatment of Parkinson's disease [J]. Annu Rev Med, 2004, 55: 41-60.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部